Co Founder & Chairman
Kaizen Biosciences
Disclosure(s): Kaizen Biosciences: Board Member, Ownership Interest, Stocks/Bonds (Private Company)
Keith Dewedoff is Co-Founder and Executive Chair of Kaizen Biosciences, a clinical-stage biotechnology company committed to “Change. For the Better.” At Kaizen, he helps lead strategy at the intersection of biotechnology, drug development, and data science, with a focus on capital-efficient innovation in areas often overlooked by big pharma. Trained in nanomedicine at the University of Oxford, Keith’s scientific background centers on the design and translation of therapeutic delivery systems. He has co-authored peer-reviewed publications and presented research at international conferences, including IATDMCT 2024. His work integrates translational nanomedicine, antimicrobial innovation, and machine learning models to accelerate drug discovery, optimize PK/PD modeling, and inform model-driven clinical development. Keith is committed to bridging computational tools, experimental science, and entrepreneurial execution to deliver transformative therapies, particularly in combating antimicrobial resistance and expanding access to cost-effective solutions for patients worldwide.